Share price movements

On May 13, Teva Pharmaceutical (TEVA) closed at $12.23, 14.83% lower than its previous day’s close, 12.89% lower than its 52-week low of $14.04, and 52.89% lower than its 52-week high of $25.96. The company’s market cap is $13.54 billion, and its forward PE, PS (price-to-sales), PB (price-to-book), and PC (price-to-cash) ratios are 4.75, 0.75x, 0.90x, and 6.86x, respectively.

The steep fall in its share price was triggered by a lawsuit filed by 44 US states accusing it of price-fixing in collusion with 19 other drug companies.

What Are Analysts Recommending for TEVA and ENDP in May?

Teva Pharmaceutical’s 14-day RSI (relative strength index) is currently 20.75. The company’s number of outstanding shares is 1.11 billion, while its short float ratio is 1.73%.

On May 13, Endo International (ENDP) closed at $6.51, 19.23% lower than its previous day’s close, 9.97% higher than its 52-week low of $5.92, and 64.81% lower than its 52-week high of $18.50. The company’s market cap is $1.46 billion, and its forward PE, PS, and PC ratios are 2.66x, 0.50x, and 1.49x, respectively. The fall in the company’s share price was triggered by JPMorgan Chase’s changing its rating from a “neutral” to an “underweight.”

Endo International’s 14-day RSI is currently 32.31. The company’s current number of outstanding shares is 224.64 million, while its short float ratio is 9.44%.

Analysts’ recommendations and target prices

The consensus recommendation for both Teva Pharmaceutical and Endo International is a “hold.”

Wall Street analysts expect Teva Pharmaceutical to have a potential upside of 53.80% based on the stock’s closing price on May 13. Analysts have gradually reduced the stock’s 12-month consensus target price from $21.23 in February to $20.50 in March to $19.90 in April and finally to $18.81 in May.

Of the 26 analysts covering Teva Pharmaceutical, two have given it “strong buys,” four have given it “buys,” 18 have given it “holds,” and two have given it “sells.”

Analysts expect a potential upside of 107.37% for Endo International based on the stock’s closing price on May 13. Analysts have gradually reduced the company’s 12-month consensus target price from $15.96 in February to $14.42 in March to $14.17 in April and finally to $13.50 in May.

Of the 15 analysts covering Endo International, two have given it “strong buys,” two have given it “buys,” ten have given it “holds,” and one has given it a “sell.”

Latest articles

19 Jul

Afya's IPO Sees Strong Listing Gains

WRITTEN BY Mohit Oberoi, CFA

Afya (AFYA) listed on the Nasdaq Global Select Market on July 19. The company priced its IPO at $19 per share.

19 Jul

What to Watch For in Amazon's Q2 Earnings

WRITTEN BY Sanmit Amin

e-Commerce giant Amazon (AMZN) is scheduled to report its second-quarter earnings results after the closing bell on July 25.

19 Jul

Barrick Gold Reaches Deal to Buy Acacia Mining

WRITTEN BY Anuradha Garg

After a long standoff, Barrick Gold (GOLD) and Acacia Mining (ABGLF) have reached an agreement.

19 Jul

Comcast Shares Pop on Goldman's Optimism

WRITTEN BY Ruchi Gupta

Comcast (CMCSA) shares popped after Goldman Sachs issued a positive note on the company recently. Goldman upgraded its rating for Comcast to "buy" from "hold."

19 Jul

Why Analysts Are Bearish on Netflix Stock

WRITTEN BY Aditya Raghunath

Netflix stock fell over 10.0% on Thursday and is down 0.5% today as well.

On Thursday, pet retailer Chewy (CHWY) reported its first-quarter results after the market closed. The company reported its earnings for the first time.